Last reviewed · How we verify

Sodium Valproate treatment

University of Pittsburgh · FDA-approved active Small molecule

Sodium Valproate treatment is a Histone deacetylase inhibitor; anticonvulsant Small molecule drug developed by University of Pittsburgh. It is currently FDA-approved for Epilepsy and seizure disorders, Bipolar disorder, Migraine prophylaxis. Also known as: Depakote.

Sodium valproate inhibits histone deacetylase (HDAC) and enhances gamma-aminobutyric acid (GABA) neurotransmission in the central nervous system.

Sodium valproate inhibits histone deacetylase (HDAC) and enhances gamma-aminobutyric acid (GABA) neurotransmission in the central nervous system. Used for Epilepsy and seizure disorders, Bipolar disorder, Migraine prophylaxis.

At a glance

Generic nameSodium Valproate treatment
Also known asDepakote
SponsorUniversity of Pittsburgh
Drug classHistone deacetylase inhibitor; anticonvulsant
TargetHistone deacetylase (HDAC); GABA metabolism
ModalitySmall molecule
Therapeutic areaNeurology; Oncology
PhaseFDA-approved

Mechanism of action

Sodium valproate increases GABA levels by inhibiting GABA catabolism and enhancing GABA synthesis, leading to increased inhibitory neurotransmission. Additionally, it acts as a histone deacetylase inhibitor, which affects gene expression and has been investigated for epigenetic effects in various conditions including cancer and neurological disorders.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Sodium Valproate treatment

What is Sodium Valproate treatment?

Sodium Valproate treatment is a Histone deacetylase inhibitor; anticonvulsant drug developed by University of Pittsburgh, indicated for Epilepsy and seizure disorders, Bipolar disorder, Migraine prophylaxis.

How does Sodium Valproate treatment work?

Sodium valproate inhibits histone deacetylase (HDAC) and enhances gamma-aminobutyric acid (GABA) neurotransmission in the central nervous system.

What is Sodium Valproate treatment used for?

Sodium Valproate treatment is indicated for Epilepsy and seizure disorders, Bipolar disorder, Migraine prophylaxis, Investigational use in certain malignancies (HDAC inhibition).

Who makes Sodium Valproate treatment?

Sodium Valproate treatment is developed and marketed by University of Pittsburgh (see full University of Pittsburgh pipeline at /company/university-of-pittsburgh).

Is Sodium Valproate treatment also known as anything else?

Sodium Valproate treatment is also known as Depakote.

What drug class is Sodium Valproate treatment in?

Sodium Valproate treatment belongs to the Histone deacetylase inhibitor; anticonvulsant class. See all Histone deacetylase inhibitor; anticonvulsant drugs at /class/histone-deacetylase-inhibitor-anticonvulsant.

What development phase is Sodium Valproate treatment in?

Sodium Valproate treatment is FDA-approved (marketed).

What are the side effects of Sodium Valproate treatment?

Common side effects of Sodium Valproate treatment include Tremor, Weight gain, Alopecia (hair loss), Thrombocytopenia, Hepatotoxicity, Pancreatitis.

What does Sodium Valproate treatment target?

Sodium Valproate treatment targets Histone deacetylase (HDAC); GABA metabolism and is a Histone deacetylase inhibitor; anticonvulsant.

Related